Back to search
Familial Pulmonary Fibrosis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Familial Pulmonary Fibrosis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Familial Pulmonary Fibrosis trials you may qualify forThis study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tiss…
Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free…
The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology di…
This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP). FIP is the familial form…
Pulmonary fibrosis (PF) is a progressive lung disease marked by tissue scarring and impaired breathing. Familial pulmonary fibrosis (FPF) makes up 10-20% of PF…
Chronic hepatitis B can develop into cirrhosis and liver cancer, which seriously endangers the life and health of people. In China, HBV is mainly transmitted fr…
The aim of this observational study was to understand the prognostic imaging of the degree of intratumoral fibrosis and intratumoral α-SMA levels in patients wi…
Individuals with fibrotic interstitial lung diseases (FILD) will be recruited after providing informed consent. in addition to routine data as usually collected…
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.